Intrexon | XON - Cost Of Sales


Intrexon reported $1.01M in Cost of Sales for its fiscal quarter ending in June of 2024.





Cost Of Sales Change Date
Agenus USD 642K 399K Sep/2025
Alaunos Therapeutics USD 0 18K Sep/2024
Amgen USD 1.79B 128M Dec/2025
Anika Therapeutics USD 11.44M 797K Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Heron Therapeutics USD 11.12M 795K Dec/2025
Incyte USD 121.18M 22.18M Dec/2025
Intrexon USD 1.01M 344K Jun/2024
Karyopharm Therapeutics USD 37.43M 2.41M Sep/2024
Ligand Pharmaceuticals USD 11.9M 733K Sep/2025
MacroGenics USD 10.12M 34.18M Dec/2025
MannKind USD 33.65M 13.44M Dec/2025
Merck USD 3.32B 531M Dec/2025
Novartis USD 3.54B 3M Dec/2025
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Thermo Fisher Scientific USD 7.58B 674M Dec/2025
Veracyte USD 39.28M 1.93M Dec/2025
Xencor USD 61.66M 50.95M Jun/2025